Cytokinetics CYTK Investment Proceeds
Investment Proceeds at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.
The official record: Cytokinetics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Cytokinetics's investment proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Cytokinetics's investment proceeds?
- Cytokinetics (CYTK) reported investment proceeds of $257.94M in Q1 2026.
- How has Cytokinetics's investment proceeds changed year-over-year?
- Cytokinetics's investment proceeds decreased by 6.5% year-over-year, from $275.73M to $257.94M.
- What does investment proceeds mean?
- The cash received from selling or maturing investment assets.
- How do you interpret investment proceeds?
- Higher inflows suggest the liquidation of assets to support operational cash needs or a shift in investment strategy, while lower inflows indicate a hold-to-maturity approach.
- How does investment proceeds compare across companies?
- Standard for companies managing a portfolio of short-term investments; varies based on the timing of investment maturities.